已发表论文

正在进行的以阿霉素为基础的新辅助化疗对原发性胃血管肉瘤的病理完全反应是否有替代作用?1 病例报告

 

Authors Zheng CH, Wang Y, Liu TT, Ding XY, Qu JJ, Su ZD

Received 9 September 2020

Accepted for publication 24 November 2020

Published 14 December 2020 Volume 2020:13 Pages 1515—1521

DOI https://doi.org/10.2147/IJGM.S280375

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Introduction: Angiosarcoma is a malignant tumor with low incidence. Especially in the advanced tumors, there is still a lack of knowledge of evidence-based medicine.
Case Presentation: We report a case of a 55-year-old woman with abdominal pain of 2 months of duration, which had increased in severity for 2 weeks prior to the presentation. The diagnosis is primary gastric angiosarcoma. We performed multiple disciplinary team (MDT), and doxorubicin-based neoadjuvant chemotherapy (NAC) was proposed. After two cycles of NAC, a computed tomography (CT) scan showed complete regression compared with the previous scan. An open surgery was done, and surgical specimens were confirmed as a pathological complete response (PCR) by pathological and immunohistochemical examination, but unfortunately, the patient suffered a relapse after the surgery in 3 months.
Conclusion: Repeated endoscopic biopsy and biopsy specimen examinations can improve accuracy in diagnosis. It seems that NAC could be a candidate for advanced primary gastric angiosarcomas. But after the rapid relapse, we are wondering whether pathologic complete response is the surrogate in primary gastric angiosarcoma undergoing NAC.
Keywords: gastric angiosarcoma, stomach, neoadjuvant chemotherapy, pathologic complete response